If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
178
results.
Updated on
21/02/2026 [07:40:00]
Results 100 to 125 of 178
Absstract of: AU2024236253A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Absstract of: US2025305068A1
The present invention relates to a new biomarker of inflammatory bowel disease and its uses. The new biomarker is a ratio of Dialister spp. to Phascolarctobacterium spp. This biomarker can be used for diagnosis purpose of diseases or disorders associated with an intestinal dysbiosis, for stratifying patient population in a clinical trial, for selecting a subject that will benefit from a treatment, or for monitoring treatment response. The present invention further provides new therapeutic strategies.
Absstract of: US2025304705A1
The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Absstract of: US2025302891A1
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.
Absstract of: WO2025202626A1
The present techniques relate to a breath analysis device and a system for using such a breath analysis device. We also describe a method for using the breath analysis device. The breath analysis device comprises a filtering mechanism (which may also be termed a filter stack) for removing interferent chemicals to increase the accuracy of detection, identification and quantification of specific chemicals. Exhaled human breath comprises a multiplicity of vapour phase chemicals and the function of the filtering mechanism is removal, retardation and separation of chemicals other than the specific chemicals to be determined by the sensing element(s). Removal, retardation and separation of the chemicals other than those of interest reduces error by reducing cross sensitivities when using broadly selective sensors such as metal oxide semiconductors. One example use of the breath analysis device may be to enable users who suffer from digestive health problems, particularly irritable bowel syndrome (IBS) or small intestinal bacterial overgrowth (SIBO), to monitor symptoms based on detection of specific chemicals such as hydrogen and/or methane in their breath over time.
Absstract of: WO2025206567A1
The present invention provides a miRNA biomarker for diagnosing and treating inflammatory bowel disease (IBD). A biomarker according to one embodiment of the present invention can be utilized in a composition for diagnosing inflammatory bowel disease, a method for providing information for diagnosis, a pharmaceutical composition for preventing or treating inflammatory bowel disease, and a method for treating inflammatory bowel disease.
Absstract of: JP2025143348A
To provide anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.SOLUTION: Antibodies that specifically bind to VP1 of BK virus serotypes I to IV are provided. A method for treating or reducing likelihood of BK virus or JC virus associated disorders is provided. The method comprises administering via injection or infusion to a patient in need an effective amount of the antibody or a pharmaceutical composition, wherein the disorders are nephropathy, BKVAN, hemorrhagic cystitis (HC), progressive multifocal leukoencephalopathy (PML), granule cell neuronopathy (GCN), interstitial kidney disease, ureteral stenosis, vasculitis, colitis, retinitis, meningitis, and immune reconstitution inflammatory syndrome (IRIS).SELECTED DRAWING: None
Absstract of: CN120719010A
The invention discloses an intestinal microbial marker related to irritable bowel syndrome, a product and application of the intestinal microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized in that the enteric microbial marker comprises one or more of Bacteroides multiforme, Clostridium concealum, Bacteroides ovale and Streptococcus sativus, and the enteric microbial marker comprises one or more of the following components: Bacteroides multiforme, Clostridium concealum, Bacteroides ovale and Streptococcus sativus, and the enteric microbial marker comprises one or more of Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum and Lactobacillus plantarum. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing irritable bowel syndrome and a computer program product related to the irritable bowel syndrome. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of the irritable bowel syndrome, and provides a new tool for clinical diagnosis.
Absstract of: CN120713972A
The invention discloses a traditional Chinese medicine compound for treating bowel stagnation and a preparation method, and relates to the technical field of traditional Chinese medicine preparation, the compound is prepared from the following raw materials in parts by mass: 12 parts of fried hawthorn, 12 parts of medicated leaven, 9 parts of ginger processed pinellia, 9 parts of poria cocos, 9 parts of pericarpium citri reticulatae, 9 parts of fructus forsythiae, 9 parts of radish seed, 9 parts of immature bitter orange, 9 parts of rhizoma cyperi, 6 parts of mangnolia officinalis, 9 parts of scutellaria baicalensis, 6 parts of coptis chinensis, 25 parts of raw atractylodes macrocephala koidz and 12 parts of rhizoma atractylodis. The medicated leaven in the traditional Chinese medicine compound is fried, so that the carried stale gas can be removed, the bitter taste generated in the subsequent decocting process can be reduced, thin-layer identification is performed on the fried hawthorn and the rhizoma atractylodis, the ratio can be calculated according to the distance from an original point to the center of a main spot and the distance from the original point to the front edge of a developing solvent, and the specific value can be calculated. And the property of the compound is judged, so that the decocted liquid medicine can be improved, and the gastrin level of a patient taking the liquid medicine can be effectively increased.
Absstract of: CN120695183A
The invention discloses application of CUL7 as a target spot in preparation of a medicine for preventing and/or treating colitis, and belongs to the technical field of medicine and pharmacology. The invention provides application of a CUL7 target spot in preparation of a medicine for preventing and/or treating colitis. The invention also provides application of CUL7 as a target spot in preparation of a preparation for diagnosing colitis, and application of a CUL7 gene inhibitor or a CUL7 protein inhibitor in preparation of a medicine for preventing and/or treating colitis. The invention proves the relationship between the CUL7 and the colitis, the CUL7 can be used as a target for preventing and treating the colitis, the CUL7 gene expression or the CUL7 intervention effect can be realized by utilizing any technology, the colitis can be effectively inhibited, and a basis is provided for the prevention, diagnosis and treatment of diseases.
Absstract of: CN120708939A
The invention discloses an inflammatory bowel disease curative effect prediction system based on multi-modal data, and relates to the field of medical information processing. The system comprises a multi-modal data acquisition module used for receiving multi-modal data; the text feature extraction module is used for determining a text feature vector by utilizing a text feature extraction model; the endoscopic intestinal mucosa feature recognition module is used for determining intestinal mucosa features by using an endoscopic intestinal mucosa feature recognition model; the image feature recognition module is used for determining iconography features by using an image feature recognition model; the pathological feature extraction module is used for determining pathological features by using the pathological recognition model; and the curative effect prediction module is used for predicting the curative effect of the biological agent based on the multi-modal data characteristics by using a Transform model and a full connection layer. Compared with the prior art, biological agent curative effect prediction based on clinical-pathology-endoscope-image multi-mode feature fusion is achieved, and the accuracy and clinical rationality of diagnosis and treatment decisions are improved.
Absstract of: CN120699897A
The invention discloses a method for separating colonic lamina propria cells of mice with colitis and application of the method. According to the method, separation of the propria neutrophile granulocyte on the colon tissue with the complete length is tried for the first time, and the total time required by cell separation is effectively shortened through multiple digestion reagents with different compositions, so that apoptosis of the neutrophile granulocyte caused by long-time exposure of an intestinal sample is effectively avoided; the problems of low cell yield, poor activity and the like are solved, and a new thought is provided for separation of the neutrophile granulocytes.
Absstract of: WO2025199410A1
The disclosed method and system pertain to stratifying a patient population for precision medicine in Inflammatory Bowel Disease (IBD) treatment. The method involves accessing a multi-omic dataset comprising genomic, transcriptomic, and proteomic profiles of patient data. Machine learning algorithms are employed to analyze the dataset and identify biomarkers associated with a response to a drug for treating IBD. The patient population is stratified into phenotypic groups based on the identified biomarkers using unsupervised clustering. A patient population predicted to respond to the drug is defined based on the stratification and further analysis of patient metadata. The system includes a data storage unit and a processor configured to perform the method. The method and system can be used to optimize therapeutic interventions in IBD management.
Absstract of: AU2024242428A1
Provided herein are methods for treating or preventing pouchitis comprising administering a SMAD7 antisense oligonucleotide or pharmaceutical formulations comprising the SMAD7 antisense oligonucleotide.
Absstract of: CN120683281A
The invention discloses a microbial marker for treating irritable bowel on the basis of coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker is prepared from the following components: Butyrimonas faecalis, Odoribacter laneus, Parabacteroides verdea, Bacteroides eggerii, Phocaeia massiformis, Phocaeia dorrei, Phocaeia vulgaris, Bacteroides nordii, Phocaeia viscera, Muriaceae bacteria, Clostridium fesum, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces Through metagenome sequencing and a machine learning algorithm, the key microbial markers significantly related to intestinal stress symptom improvement in the coprophilous fungus transplantation treatment process are screened out, and a scientific basis and a standardized scheme are provided for coprophilous fungus transplantation treatment of irritable bowel.
Absstract of: WO2025193919A1
Methods of identifying a canine subject susceptible to inflammatory bowel disease, methods of treating or preventing inflammatory bowel disease in a canine subject, and compositions useful for treating or preventing inflammatory bowel disease in a canine subject are described herein.
Absstract of: US2025290143A1
Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohn's disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.
Absstract of: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Absstract of: JP2025134894A
To provide a system and a method for easily and accurately detecting a defecation event and acquiring defecation event data.SOLUTION: A system 100 and a method facilitate detection and recording of a defecation event of a target such as a participant of a clinical test for treating a digestive system disease such as an irritable bowel syndrome (IBS), an inflammatory bowel disease (IBD), and chronic coprostasis. The system 100 and the method can be used by individual patients for detecting and recording a defecation event, and resultant data can be checked in detail by a medical treatment provider at the time of evaluating health and/or treatment of the gastrointestinal of the patient.SELECTED DRAWING: Figure 1
Absstract of: TW202535470A
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/ or diagnostic use in a subgroup of patients having ulcerative colitis.
Absstract of: KR20250135709A
본 발명은 장 질환 예방 또는 치료용 조성물 및 장 질환 진단을 위한 정보제공방법에 관한 것으로, 인간의 장내 마이크로바이옴 분석을 통해 장 질환과 관련있는 유효 균주를 선별하였으며, 이들 중 크론병 등 장 질환에 치료 효과가 있는 균주를 확인하였는 바, 질병 진단 또는 장 질환의 예방, 개선 및 치료에 유용하게 활용될 수 있다.
Absstract of: CN120617562A
The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method of a magnetic resonance/fluorescence bimodal nanometer diagnosis and treatment agent based on nitrogen oxide. The preparation method comprises the following steps: firstly, respectively modifying distearoyl phosphatidyl ethanolamine phospholipid and IR780 by utilizing TEMPO to prepare DSPE-PEG-TEMPO and an ROS responsive fluorescent probe IT, then embedding the phospholipid into a macrophage cell membrane by utilizing cell membrane fluidity, and wrapping the fluorescent probe IT and curcumin in an ultrasonic and extrusion manner, so as to prepare the bionic nano diagnosis and treatment agent based on MRI/FL dual-mode imaging. Wherein the TEMPO not only has MRI (Magnetic Resonance Imaging) performance, but also can remove active oxygen; the ROS response type fluorescent probe can track the focus of the inflammatory bowel disease through fluorescence imaging and is used for surgical navigation; the anti-inflammatory drug curcumin can be slowly released at the focus part. Through the synergistic effect of the three components and the inflammation tendency of the macrophage membrane, accurate imaging and drug release treatment of the inflammatory bowel disease are expected to be realized.
Absstract of: CN120617394A
The invention relates to the technical field of traditional Chinese medicines, in particular to application of a qi-stagnation stomachache preparation in preparation of a medicine for treating irritable bowel syndrome. According to the application of the qi-stagnation stomachache preparation in preparation of the medicine for treating the irritable bowel syndrome, the diarrhea condition of the diarrhea type irritable bowel syndrome can be improved, meanwhile, anxiety and visceral hypersensitivity caused by the irritable bowel syndrome can be relieved, and therefore the preparation can be used for preparing the medicine for treating the qi-stagnation stomachache. The qi stagnation and stomachache preparation has a remarkable improvement effect on diarrhea type irritable bowel syndrome (IBS-D).
Absstract of: WO2025185637A1
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Nº publicación: WO2025185773A1 12/09/2025
Applicant:
TRUELAB BIOPHARMACEUTICAL CO LTD [CN]
\u5E06\u793C\u751F\u7269\u6280\u672F\uFF08\u6B66\u6C49\uFF09\u6709\u9650\u516C\u53F8
Absstract of: WO2025185773A1
Disclosed in the present invention are an antibody targeting TL1A and the use thereof. The antibody of the present invention can be used for blocking the interaction between TL1A and DR3, is helpful for achieving the purpose of intervention from the early stages of inflammation, inhibits immune cells such as effector T cells to release cytokines for promoting an inflammatory response, and provides more possibilities for treatment methods for IBD patients or other TL1A-related diseases.
BOPI
Electronic site
